Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized study of entecavir versus lamivudine in HBV-associated acute-on-chronic liver failure
ChiCTR-TRC-12001980Phase 4Completed
- Sponsor
- Liver Failure Treatment and Research Center
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hepatitis B-related acute-on-chronic liver failure (HBV-ACLF) comparing Entecavir with Lamivudine (2 arms). Primary endpoint: Survival rate. Started Nov 2008; status: completed.
02
Drugs
entecavirlamivudine
03
Conditions
hepatitis B-related acute-on-chronic liver failure (HBV-ACLF)
Beyond the preview
Go deeper on ChiCTR-TRC-12001980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12001980.